Loading patent…
AssigneeTeva Pharmaceutical Industries Ltd.
InventorMichael HAYDEN
Estimating the term…
This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.
A method of treating a human patient afflicted with a neurodegenerative disorder comprising periodically administering to the patient an amount of laquinimod and an amount of pridopidine, wherein the amounts when taken together are effective to treat the human patient.
10-14. (canceled)
16-20. (canceled)
25-30. (canceled)
33-48. (canceled)
50-55. (canceled)
57-67. (canceled)
A package comprising
69-124. (canceled)
A pharmaceutical composition comprising an amount of laquinimod and an amount of pridopidine.
126-176. (canceled)
Dependencies are inferred from the claim text.